ALNY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
ALNY is a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. My direct view is BUY. The stock has strong long-term growth support from analyst upgrades, positive Amvuttra launch commentary, and constructive technical momentum, while options positioning is mildly bullish. The current setup looks suitable for an immediate entry rather than waiting.
ALNY is in a short-term uptrend with bullish momentum. MACD histogram is positive at 1.951 and expanding, which supports continued upside. RSI_6 at 68.921 is elevated but not yet a strong reversal signal. Moving averages are converging, suggesting the stock may be transitioning into a stronger trend phase. Price at 303.74 is just below resistance at 303.492-308.59 after testing the pivot area at 295.241, so the chart shows a constructive breakout attempt. Overall technicals favor a buy with near-term upside potential.
["Citi initiated coverage with a Buy rating and $380 target on 2026-05-18.", "Citi said the expanded launch of Amvuttra for ATTR-CM has been impressive and sees more tailwinds than headwinds.", "Bernstein noted Amvuttra beat consensus by 5% and said U.S. numbers look very strong.", "Truist remains Buy-rated and expects robust year-over-year growth.", "Options sentiment is bullish with low put-call ratios.", "Technical momentum is improving with positive MACD expansion."]
["Jefferies downgraded ALNY to Hold and cut its target sharply, calling the shares priced to perfection.", "Morgan Stanley kept Equal Weight despite raising its target.", "There is still concern from some analysts that growth expectations may already be high.", "Recent price action includes a year-to-date pullback mentioned by Citi, which may reflect lingering competition concerns.", "News flow provided is unrelated to ALNY, so there is no major fresh company-specific news catalyst in the dataset."]
No latest quarter financial snapshot was available in the data because the financial section returned an error. Based on the analyst commentary, however, the latest quarter appears to have been strong, especially for Amvuttra, which beat consensus by 5%. Analysts also cited continued U.S. strength and robust year-over-year growth, while noting some seasonal weakness in Q1 from payer dynamics and fewer shipping weeks. The latest quarter season referenced in the analyst comments is Q1.
Analyst sentiment is net positive but mixed. Recent changes show Citi starting coverage with Buy and a $380 target, Bernstein staying Outperform and slightly trimming target, and Truist remaining Buy with a higher target at $505. Morgan Stanley is more neutral at Equal Weight with a $370 target, while Jefferies turned cautious by downgrading to Hold and cutting target to $330. Wall Street pros mostly like the long-term growth story and Amvuttra momentum, while the main con is valuation and concern that expectations may already be rich.
